Literatur: Ticagrelor

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Ticagrelor

• 1. Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” Can J Cardiol, 2011, 27(Suppl A):1-59. [PubMed 21640290]
• 2. Cannon CP, Harrington RA, James S, et al, “Comparison of Ticagrelor With Clopidogrel in Patients With a Planned Invasive Strategy for Acute Coronary Syndromes (PLATO): A Randomised Double-Blind Strategy,” Lancet, 2010, 375(9711):283-93. [PubMed 20079528]
• 3. Gaglia MA Jr and Waksman R, "Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor," Circulation, 2011, 123(4):451-6. [PubMed 21242480]
• 4. Gurbel PA, Bliden KP, Butler K, et al, “Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study,” Circulation, 2009, 120(25):2577-85. [PubMed 19923168]
• 5. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
• 6. Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42. [PubMed 22064600]
• 7. James S, Akerblom A, Cannon CP, et al, “Comparison of Ticagrelor, the First Reversible Oral P2Y12 Receptor Antagonist, With Clopidogrel in Patients With Acute Coronary Syndromes: Rationale, Design, and Baseline Characteristics of the Platelet inhibition and Patient Outcomes (PLATO) Trial,” Am Heart J, 2009, 157(4):599-605. [PubMed 19332184]
• 8. James S, Budaj A, Aylward P, et al, “Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial,” Circulation, 2010, 122(11):1056-67. [PubMed 20805430]
• 9. James SK, Roe MT, Cannon CP, et al, “Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Intended for Non-invasive Management: Substudy from Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial,” BMJ, 2011, 342:d3527. [PubMed 21685437]
• 10. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
• 11. Mahaffey KW, Wojdyla DM, Carroll K, et al, “Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial,” Circulation 2011, 124(5):544-54. [PubMed 21709065]
• 12. Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” Circulation, 2011, 124(22):2458-73. [PubMed 22052934]
• 13. Wallentin L, Becker RC, Budaj A, et al, “Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndromes,” N Engl J Med, 2009, 361(11):1045-57. [PubMed 19717846]

 

  top |